EUCTR2004-001183-41-CZ进行中（未招募）不适用
A 6-month, double-blind, double-dummy, randomised, parallel group, multicenter, efficacy and safety study of Symbicort® pMDI 2x160/4.5µg and 2x80/4.5µg bid compared to Formoterol Turbuhaler, Budesonide pMDI (& the combination) and Placebo in chronic obstructive pulmonary disease patients (COPD). - SHINE
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Signed written informed consent from the patient.
- •2.Outpatients, men or women ³ 40 years of age.
- •3.Clinical diagnosis of COPD, with COPD symptoms for more than 2 years.
- •4.Smoking, current or previous, with a smoking history ³ 10 pack years.
- •5.Pre-bronchodilatory FEV1 £50% of predicted normal value.
- •6.Pre-bronchodilatory FEV1/VC <70 %
- •7.Documented use of short-acting inhaled bronchodilatator ( ß2-agonist or anticholinergics) as rescue medication.
- •8.A score of ³ 2 on the MMRC dyspnoea scale.
- •9.A history of at least one COPD exacerbation requiring a course of oral steroids and/or antibiotics within 1-12 months prior to Visit 1 (ie, not within the 30 days prior to Visit 1).
- •10.At Visit 2: Total symptom score of 2 or more per day for at least half of the run-in period (by totalling the Breathlessness Diary, cough and sputum scores from the diary card).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.A history of asthma (National Institutes of Health 2002).
- •2.A history allergic rhinitis before 40 years of age.
- •3.Significant or unstable ischemic heart disease, arrhythmia, cardiomyopathy, heart failure, uncontrolled hypertension as defined by the investigator, or any other relevant cardiovascular disorder as judged by the investigator.
- •4.Any current respiratory tract disorders other than COPD, which is considered by the investigator to be clinically significant.
- •5.Known homozygous Alpha-1 antitrypsin deficiency.
- •6.Any significant disease or disorder (e.g. gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment, current peptic ulcer or history of steroid-induced peptic ulcer) which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patients ability to participate in the study.
- •7.Patients who have needed additions or alterations to their usual maintenance or rescue therapy for COPD due to worsening symptoms within the 30 days prior to Visit 1.
- •8.Use of oral or ophthalmic non-cardio-selective b-blocking agents.
- •9.Use of oral steroids.
- •10.Participation in a COPD rehabilitation program within 6 months prior to the study or who are scheduled for such a programme during the study.
- •11.Known or suspected hypersensitivity to study therapy or excipients.
- •12.Scheduled in-patient hospitalisation during the course of the study.
- •13.Pregnancy, breast-feeding or planned pregnancy during the study. Fertile women not using acceptable contraceptive measures, as judged by the investigator. Female patients who are not post-menopausal or surgically sterile must have a negative pregnancy test prior to randomisation.
- •14.Participation in a clinical study evaluating an investigational drug in the last 30 days prior to Visit 1, or previous allocation of a randomisation code in this study (if a patient has previously been enrolled, fulfilled all the inclusion criteria and none of the exclusion criteria at Visit 1, but was not eligible to be randomized due to worsening COPD symptoms in the run-in period, the patient may be enrolled into the study a second time).
- •15.Previous participation in a Symbicort pMDI clinical study.
- •16.A history of any condition associated with poor compliance.
- •17.Involvement in the planning or conduct of the study (applies to both AstraZeneca staff and staff at the Investigator site).
- •18.At Visit 2: patient who have needed additions or alterations to their usual maintenance or rescue therapy for COPD due to worsening symptoms since Visit 1.
研究者
相似试验
进行中（未招募）
1 期
A study with lifestyle intervention and study medication once weekly or lifestyle intervention and placebo in adolescents with obesity to explore differences between groups with regard to change in BMI.Obesity in adolescentsEUCTR2015-001628-45-SEDep. of Medical Cell Biology Uppsala University44
进行中（未招募）
不适用
The study is measuring the safety and effect of the study drug zicronapine in the treatment of patients with schizophrenia. Patients will receive either the study drug (zicronapine) or risperidone based on a computer-aided random draw, and no one involved in the study will know what treatment is given until the study has finished.MedDRA version: 14.0Level: PTClassification code 10039638Term: Schizophrenia, disorganised typeSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 14.0Level: PTClassification code 10039639Term: Schizophrenia, paranoid typeSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 14.0Level: PTClassification code 10052792Term: Schizophrenia, undifferentiated typeSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 14.0Level: PTClassification code 10039637Term: Schizophrenia, catatonic typeSystem Organ Class: 10037175 - Psychiatric disordersSchizophreniaEUCTR2010-022181-28-PLH. Lundbeck A/S160
进行中（未招募）
不适用
A 6-month, randomised, double-blind, parallel-group, risperidone-controlled, fixed-dose study evaluating the safety and efficacy of zicronapine in patients with schizophreniaSchizophreniaEUCTR2010-022181-28-CZH. Lundbeck A/S160
进行中（未招募）
不适用
The study is measuring the safety and effect of the study drug zicronapine in the treatment of patients with schizophrenia. Patients will receive either the study drug (zicronapine) or risperidone based on a computer-aided random draw, and no one involved in the study will know what treatment is given until the study has finished.SchizophreniaEUCTR2010-022181-28-FIH. Lundbeck A/S160
进行中（未招募）
不适用
The study is measuring the safety and effect of the study drug zicronapine in the treatment of patients with schizophrenia. Patients will receive either the study drug (zicronapine) or risperidone based on a computer-aided random draw, and no one involved in the study will know what treatment is given until the study has finished.SchizophreniaEUCTR2010-022181-28-EEH. Lundbeck A/S160